Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Single and Dual Targeting Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia

Sneha Chitre, PhD, Joop Gaken, PhD, Andrea Venuso, Masters, Ghulam J. Mufti, Professor

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-142013

Published: 2020

Journal Articles

Mir-181c Modulates T Cell Function By Regulating the Expression of BRK1

Shok Ping Lim, Donal McLornan, MB, Bch (Hons), PhD MRCP, FRCPath, Nikolaos Ioannou, David Darling, Alan G. Ramsay, PhD, Joop Gäken, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2016) 128 (22): 132.

https://doi.org/10.1182/blood.V128.22.132.132

Published: 2016

Journal Articles

Comparison of Peripheral Blood and Bone Marrow Molecular Profiling in Primary Myelodysplastic Syndromes (MDS)

Azim M Mohamedali, PhD, Joop Gaken, PhD, Momin Ahmed, MD PhD, Austin Kulasekararaj, Alexander E Smith, PhD, Farook Malik, PhD, Ghulam Mufti, MD DM, FRCP, FRCPath

Blood (2014) 124 (21): 4655.

https://doi.org/10.1182/blood.V124.21.4655.4655

Published: 2014

Journal Articles

RPL27A Is a Target for Mir-595 and Contributes to Myelodysplastic Phenotype through Ribosomal Dysgenesis

Heba A Alkhatabi, MSc, Joop Gaken, PhD, Austin Kulasekararaj, Shengjiang Tan, PhD, Farooq Malik, BSc, PhD, Alan John Warren, PhD FRCP, FRCPath, FMedSci, Thomas Seidl, David C Darling, PhD, Ghulam Mufti, MD DM, FRCP, FRCPath

Blood (2014) 124 (21): 1895.

https://doi.org/10.1182/blood.V124.21.1895.1895

Published: 2014

Journal Articles

Comprehensive Mutational Screening Of 5-Azacitidne Treated Myelodysplastic Syndrome (MDS) Patients Fails To Identify a Specific Mutational Profile Predicting Response To Therapy

Austin G. Kulasekararaj, Azim M Mohamedali, PhD, Alexander E Smith, PhD, Syed A Mian, Nazia Matto, Terry J Gaymes, DPhil, Nicholas Lea, PhD, Joop Gaken, PhD, Ghulam J. Mufti, DM, FRCP, FRCPath

Blood (2013) 122 (21): 2792.

https://doi.org/10.1182/blood.V122.21.2792.2792

Published: 2013

Journal Articles

Utility of Peripheral Blood for Cytogenetic and Mutation Analysis in Myelodysplastic Syndrome

Heba A Alkhatabi, MSc, Azim M Mohamedali, PhD, Austin G Kulasekararaj, Sneha Shinde, Msc., Joop Gaken, PhD, Syed A Mian, MSc, Alexander E Smith, PhD, Ghulam J. Mufti, MD

Blood (2012) 120 (21): 1707.

https://doi.org/10.1182/blood.V120.21.1707.1707

Published: 2012

Journal Articles

Prevalence of 46/1 JAK2 Haplotype in Patients with Budd-Chiari Syndrome with and without JAK2V617F and TET2 Mutations.

Nicholas C Lea, PhD, Lara N Roberts, Raj K Patel, Rachel Westbrook, Michael A Heneghan, Azim M Mohamedali, PhD, Alex E Smith, Atiyeh Abdallah, Nigel Westwood, PhD, CSci, FIBMS, Trisevgeni Kontou, Deborah Yallop, BSc, FRCPath, MB, BS, MRCP, Roopen Arya, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Joop Gaken, PhD, Nigel D Heaton, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2009) 114 (22): 434.

https://doi.org/10.1182/blood.V114.22.434.434

Published: 2009

Journal Articles

Deep Sequencing the Tet2 Gene in 360 Patients with Myeloid Neoplasms Provides a Comprehensive and Quantitative Mutation Map and Reveals Low Level Mutant Clones.

Alexander E Smith, Azim M Mohamedali, PhD, Syed a Mian, Technician, Nicholas C Lea, BSc, PhD, Nigel Westwood, PhD, CSci, FIBMS, Austin G Kulasekararaj, Joop Gaken, PhD, Corinna Strupp, Norbert Gattermann, MD, PhD, Ulrich Germing, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2009) 114 (22): 733.

https://doi.org/10.1182/blood.V114.22.733.733

Published: 2009

Journal Articles

High Resolution Genomic Mapping of Breast Cancer Derived T-MDS/TAML

Azim M Mohamedali, PhD, Natalie Twine, MSc, Joop Gaken, PhD, Nigel Westwood, PhD, CSci, FIBMS, Nicholas Lea, PhD, Rajani Chelliah, MSc, Detlef Haase, MD, PhD, Ghulam J Mufti, FRCP, FRCPath

Blood (2008) 112 (11): 2692.

https://doi.org/10.1182/blood.V112.11.2692.2692

Published: 2008

Journal Articles

MicroRNA Expression Profiling of High and Low Risk MDS

Joop Gaken, PhD, Azim M Mohamedali, PhD, Natalie Twine, Nigel Westwood, PhD, CSCI, FIBMS, Barbara Czepulkowski, Saousan Chehade, Lynn S Quek, Nicholas Lea, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2008) 112 (11): 3645.

https://doi.org/10.1182/blood.V112.11.3645.3645

Published: 2008

Journal Articles

High Resolution Molecular Analysis of 5q- Syndrome Patients at Diagnosis and Following Lenalidomide Therapy

Azim M Mohamedali, PhD, Nicholas Lea, PhD, Natalie Twine, MSc, Joop Gaken, PhD, Rajani Chelliah, MSc, Nigel Westwood, PhD, CSci, FIBMS, Ghulam J Mufti, FRCP, FRCPath

Blood (2008) 112 (11): 225.

https://doi.org/10.1182/blood.V112.11.225.225

Published: 2008

Journal Articles

Kinesin Family Member 20A (KIF20A) Is Specifically down Regulated in 5q- CD34+ and CD61+ Cells and Uniparental Disomy Is Not a Feature of 5q- Syndrome.

Nicholas C. Lea, PhD, Azim Mohamedali, PhD, Natalie Twine, MSc, Joop Gaken, Phd, Nigel Westwood, Phd, Wendy Ingram, MBBS, Ghulam Mufti, MD

Blood (2006) 108 (11): 2611.

https://doi.org/10.1182/blood.V108.11.2611.2611

Published: 2006

Journal Articles

TAT-Apoptin Mediated Induction of Apoptosis in Leukaemic Cells.

Joop Gaken, PhD, Louisa Pericleous, PhD, Farzin Farzaneh, PhD, Ghulam J. Mufti, MD, Mahvash Tavassoli, PhD

Blood (2006) 108 (11): 1900.

https://doi.org/10.1182/blood.V108.11.1900.1900

Published: 2006

Journal Articles

Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome.

Raj K. Patel, MD, Nicholas Lea, PhD, Michael A. Heneghan, MD, Nigel Westwood, PhD, Dragana Milojkovic, MD, Kumar Thanigaikumar, MD, Deborah Yallop, MD, Roopen Arya, PhD, Antonio Pagliuca, MD, Joop Gaken, PhD, Nigel A. Heaton, MD, Ghulam J. Mufti, MD

Blood (2005) 106 (11): 2588.

https://doi.org/10.1182/blood.V106.11.2588.2588

Published: 2005

NARROW

Single and Dual Targeting Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia

Mir-181c Modulates T Cell Function By Regulating the Expression of BRK1

Comparison of Peripheral Blood and Bone Marrow Molecular Profiling in Primary Myelodysplastic Syndromes (MDS)

RPL27A Is a Target for Mir-595 and Contributes to Myelodysplastic Phenotype through Ribosomal Dysgenesis

Comprehensive Mutational Screening Of 5-Azacitidne Treated Myelodysplastic Syndrome (MDS) Patients Fails To Identify a Specific Mutational Profile Predicting Response To Therapy

Utility of Peripheral Blood for Cytogenetic and Mutation Analysis in Myelodysplastic Syndrome

Prevalence of 46/1 JAK2 Haplotype in Patients with Budd-Chiari Syndrome with and without JAK2V617F and TET2 Mutations.

Deep Sequencing the Tet2 Gene in 360 Patients with Myeloid Neoplasms Provides a Comprehensive and Quantitative Mutation Map and Reveals Low Level Mutant Clones.

High Resolution Genomic Mapping of Breast Cancer Derived T-MDS/TAML

MicroRNA Expression Profiling of High and Low Risk MDS

High Resolution Molecular Analysis of 5q- Syndrome Patients at Diagnosis and Following Lenalidomide Therapy

Kinesin Family Member 20A (KIF20A) Is Specifically down Regulated in 5q- CD34+ and CD61+ Cells and Uniparental Disomy Is Not a Feature of 5q- Syndrome.

TAT-Apoptin Mediated Induction of Apoptosis in Leukaemic Cells.

Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only